AUSTIN, Texas--(BUSINESS WIRE)--Introgen Therapeutics, Inc. (NASDAQ:INGN) announced today that it will host a conference call to discuss its fourth quarter and year end results. During the call, Introgen will also provide updates on its regulatory and clinical developments. Introgen will confirm its guidance for ADVEXIN filings which remain on track and are advancing in both the United States and Europe. In addition, management will comment upon recently published false and misleading internet articles and other developments.
